<DOC>
	<DOCNO>NCT01536145</DOCNO>
	<brief_summary>This study represent first-in-human study CP-751,871 . The study aim define safety , tolerability , maximum tolerate dose CP-751,871 patient multiple myeloma dose escalation design .</brief_summary>
	<brief_title>CP-751,871 Treatment For Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Previously treat multiple myeloma quantifiable serum ( M spike ≥ 1 g/dL ) and/or urine ( ≥ 200 mg/24hr ) paraprotein Adequate bone marrow , renal , liver cardiac function Eastern Cooperative Oncology Group [ ECOG ] performance status less equal 2 Prior allogeneic stem cell transplant ( alloSCT ) Myelosuppressive chemotherapy immunotherapy within 3 week prior treatment CP751,871 Prior organ allograft Concurrent use insulin , oral hypoglycemic medication , growth hormone ( GH ) , growth hormone inhibitor Female patient pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>IGF-1R inhibitor</keyword>
	<keyword>CP-751871</keyword>
	<keyword>multiple myeloma</keyword>
</DOC>